RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+31.2%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.93B
AUM Growth
+$4.93B
(+5.2%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
50.68%
Holding
90
New
9
Increased
17
Reduced
11
Closed
20
Top Buys
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$95M |
| 2 |
Vor Biopharma
VOR
|
$77.3M |
| 3 |
Avidity Biosciences
RNA
|
$72.9M |
| 4 |
Vaxcyte
PCVX
|
$61.2M |
| 5 |
Acrivon Therapeutics
ACRV
|
$55.4M |
Top Sells
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$180M |
| 2 |
Biogen
BIIB
|
$112M |
| 3 |
Ascendis Pharma
ASND
|
$74.6M |
| 4 |
Relmada Therapeutics
RLMD
|
$74M |
| 5 |
Solid Biosciences
SLDB
|
$48.1M |
Sector Composition
| 1 | Healthcare | 99.36% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $850M | 17.23% | 6,957,179 -610,721 | -8% | -$74.6M |
|
|
2
Vaxcyte
PCVX
$4B
| $281M | 5.7% | 5,857,459 +1,276,256 | +28% | +$61.2M |
|
|
JBIO
3
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $242M | 4.91% | 8,263,982 | – | – |
|
|
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $214M | 4.33% | 6,848,911 +1,640,000 | +31% | +$51.2M |
|
|
VRNA
5
Verona Pharma
VRNA
$9.16B
| $165M | 3.35% | 6,317,990 +267,990 | +4% | +$7M |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $161M | 3.26% | 5,516,067 +45,000 | +0.8% | +$1.31M |
|
7
Day One Biopharmaceuticals
DAWN
$769M
| $152M | 3.07% | 7,040,622 | – | – |
|
|
8
Vor Biopharma
VOR
$250M
| $151M | 3.07% | 22,748,880 +11,627,907 | +105% | +$77.3M |
|
|
9
Biogen
BIIB
$19.4B
| $148M | 2.99% | 532,892 -404,657 | -43% | -$112M |
|
10
Cytek Biosciences
CTKB
$527M
| $137M | 2.77% | 13,381,054 | – | – |
|
11
Legend Biotech
LEGN
$6.41B
| $122M | 2.47% | 2,436,223 +97,613 | +4% | +$4.87M |
|
|
12
Avidity Biosciences
RNA
$5.99B
| $121M | 2.45% | 5,454,533 +3,287,142 | +152% | +$72.9M |
|
13
Wave Life Sciences
WVE
$1.53B
| $120M | 2.44% | 17,202,009 | – | – |
|
14
Janux Therapeutics
JANX
$1.37B
| $114M | 2.32% | 8,670,644 | – | – |
|
15
89bio
ETNB
$1.34B
| $114M | 2.31% | 8,955,410 +1,172,741 | +15% | +$14.9M |
|
16
PepGen
PEPG
$38M
| $109M | 2.21% | 8,131,952 | – | – |
|
|
IMGN
17
DELISTED
Immunogen Inc
IMGN
| $108M | 2.2% | 21,853,958 +112,500 | +0.5% | +$558K |
|
|
BLU
18
DELISTED
BELLUS Health Inc.
BLU
| $102M | 2.08% | 12,452,574 +1,067,000 | +9% | +$8.77M |
|
|
INBX
19
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $95M | 1.93% | +3,853,867 | New | +$95M |
|
20
Celldex Therapeutics
CLDX
$1.47B
| $92.5M | 1.88% | 2,075,000 | – | – |
|
21
iTeos Therapeutics
ITOS
| $86.3M | 1.75% | 4,417,259 | – | – |
|
22
Travere Therapeutics
TVTX
$1.56B
| $83.8M | 1.7% | 3,984,681 -938,260 | -19% | -$19.7M |
|
23
Cogent Biosciences
COGT
$1.69B
| $69.4M | 1.41% | 5,999,481 +1,986,028 | +49% | +$23M |
|
24
Aclaris Therapeutics
ACRS
$209M
| $69.3M | 1.41% | 4,398,453 | – | – |
|
25
Fulcrum Therapeutics
FULC
$351M
| $69.2M | 1.4% | 9,505,925 +2,505,925 | +36% | +$18.2M |
|